Evidence map›Paper›PMID 40055382›Full record

ArticleNPJ breast cancer2025

Machine learning-based spatial characterization of tumor-immune microenvironment in the EORTC 10994/BIG 1-00 early breast cancer trial.

Ioannis Zerdes, Alexios Matikas, Artur Mezheyeuski, Georgios Manikis, Balazs Acs, Hemming Johansson, Ceren Boyaci, Caroline Boman, Coralie Poncet, Michail Ignatiadis and 7 more

Registry-linked trialAbstract read
In one paragraph

Article in NPJ breast cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00017095 (First Prospective Intergroup Translational Research Trial Assessing the Potential Predictive Value of p53 Using a Functional Assay in Yeast in Patients With Locally Advanced/Inflammatory or Large Operable Breast Cancer Prospectively Randomised to a Taxane Versus a Non Taxane Regimen), which is not on this map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00017095 phase3completednot on this map

First Prospective Intergroup Translational Research Trial Assessing the Potential Predictive Value of p53 Using a Functional Assay in Yeast in Patients With Locally Advanced/Inflammatory or Large Operable Breast Cancer Prospectively Randomised to a Taxane Versus a Non Taxane Regimen

TypeinterventionalSponsorEuropean Organisation for Research and Treatment of Cancer - EORTCRan2001Enrolled1,856ConditionsBreast CancerArmsfilgrastim, cyclophosphamide, docetaxel, epirubicin hydrochloride, fluorouracil
3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Ioannis Zerdes *Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden. ioannis.zerdes@ki.se.ORCID http://orcid.org/0000-0002-8304-2462
Alexios Matikas *Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.ORCID http://orcid.org/0000-0002-4122-9624
Artur MezheyeuskiDepartment of Immunology, Genetics, and Pathology, Uppsala University, Uppsala, Sweden.
Georgios ManikisDepartment of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.ORCID http://orcid.org/0000-0002-3396-0644
Balazs AcsDepartment of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.ORCID http://orcid.org/0000-0002-0972-4633
Hemming JohanssonDepartment of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
Ceren BoyaciDepartment of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.ORCID http://orcid.org/0000-0001-5598-0243
Caroline BomanDepartment of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
Coralie PoncetEuropean Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium.
Michail IgnatiadisDepartment of Medical Oncology, Institut Jules Bordet and L'Université Libre de Bruxelles (U.L.B), Brussels; Academic Trials Promoting Team (ATPT), Institut Jules Bordet, Brussels, Belgium.ORCID http://orcid.org/0000-0002-4493-3748
Yalai BaiDepartment of Pathology, Yale School of Medicine, New Haven, CT, USA.ORCID http://orcid.org/0000-0003-4636-0143
David L RimmDepartment of Pathology, Yale School of Medicine, New Haven, CT, USA.ORCID http://orcid.org/0000-0001-5820-4397
David CameronEdinburgh University Cancer Centre, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, UK.
Hervé BonnefoiDepartment of Medical Oncology, Institut Bergonié Unicancer, INSERM U1312, Université de Bordeaux, Bordeaux, France.
Jonas BerghDepartment of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.ORCID http://orcid.org/0000-0001-5526-1847
Gaetan MacGroganDepartment of Biopathology, Institut Bergonié Unicancer, INSERM U1312, Bordeaux, France.ORCID http://orcid.org/0000-0002-3483-9758
Theodoros FoukakisDepartment of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.ORCID http://orcid.org/0000-0001-8952-9987

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Breast cancer (BC) represents a heterogeneous ecosystem and elucidation of tumor microenvironment components remains essential. Our study aimed to depict the composition and prognostic correlates of immune infiltrate in early BC, at a multiplex and spatial resolution. Pretreatment tumor biopsies from patients enrolled in the EORTC 10994/BIG 1-00 randomized phase III neoadjuvant trial (NCT00017095) were used; the CNN11 classifier for H&E-based digital TILs (dTILs) quantification and multiplex immunofluorescence were applied, coupled with machine learning (ML)-based spatial features. dTILs were higher in the triple-negative (TN) subtype, and associated with pathological complete response (pCR) in the whole cohort. Total CD4+ and intra-tumoral CD8+ T-cells expression was associated with pCR. Higher immune-tumor cell colocalization was observed in TN tumors of patients achieving pCR. Immune cell subsets were enriched in TP53-mutated tumors. Our results indicate the feasibility of ML-based algorithms for immune infiltrate characterization and the prognostic implications of its abundance and tumor-host interactions.

Identifiers

PMID40055382
PMCPMC11889191

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.